Product
Dabrafenib
Aliases
BRAF inhibitor, BRAF Inhibitor GSK2118436, Dabrafenib Mesylate, Dabrafenib Methanesulfonate (10 other aliases)
Name
Tafinlar
FDA Approved
Yes
48 clinical trials
1 organization
1 drug
119 indications
1 document
Indication
BRAF V600 Colorectal CancerIndication
Solid TumorsIndication
MelanomaIndication
Diffuse AstrocytomaIndication
Anaplastic AstrocytomaIndication
AstrocytomaIndication
OligodendrogliomaIndication
ChildhoodIndication
GlioblastomaIndication
Pilocytic AstrocytomaIndication
Giant Cell AstrocytomaIndication
Pleomorphic XanthoastrocytomaIndication
Anaplastic Pleomorphic XanthoastrocytomaIndication
Angiocentric GliomaIndication
Chordoid Glioma of Third VentricleIndication
GangliocytomaIndication
gangliogliomaIndication
Anaplastic GangliogliomaIndication
Gangliocytoma of the CerebellumIndication
Papillary Glioneuronal TumorIndication
Rosette-forming Glioneuronal TumorIndication
Central NeurocytomaIndication
Extraventricular NeurocytomaIndication
Cerebellar EpineurocytomaIndication
Small Cell Lung CarcinomaIndication
Thyroid CancerIndication
AdjuvantIndication
CancerIndication
cancerIndication
Non-Small Cell LungIndication
BRAFIndication
BRAF V600K Mutation PresentIndication
Anaplastic Thyroid CarcinomaIndication
Stage IV melanomaIndication
Stage III MelanomaIndication
Stage IV Cutaneous MelanomaIndication
Brain MetastasesIndication
Metastatic MelanomaIndication
Advanced CancerIndication
Solid TumorIndication
Haematological MalignancyIndication
BCR-ABL1-positiveIndication
Breast Cancer, Stage IVIndication
AnaemiaIndication
melanomaIndication
Stage III Cutaneous Melanoma AJCC v7Indication
AmeloblastomaIndication
BRAF gene mutationIndication
Thyroid Gland Squamous Cell CarcinomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Hodgkin lymphomaIndication
Non-Hodgkin LymphomaIndication
Hodgkin Lymphoma, Ann Arbor Stage IVIndication
Stage IV Non-Hodgkin LymphomaIndication
Atypical chronic myeloid leukemiaIndication
BCR-ABL1 NegativeIndication
Blast Phase Chronic Myelogenous LeukemiaIndication
Castration-Resistant Prostate CarcinomaIndication
Chronic Myelogenous LeukemiaIndication
Pancreatic CancerIndication
Breast CancerIndication
Metastatic Malignant Solid NeoplasmIndication
UnclassifiableIndication
Primary MyelofibrosisIndication
Acute Lymphoblastic LeukemiaIndication
Recurrent Acute Myeloid LeukemiaIndication
Chronic Lymphocytic LeukemiaIndication
Recurrent Hematologic MalignancyIndication
Hodgkin LymphomaIndication
Myelodysplastic SyndromeIndication
Myeloproliferative NeoplasmIndication
Multiple MyelomaIndication
Small Lymphocytic LymphomaIndication
Acute Myeloid LeukemiaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Refractory Hematologic MalignancyIndication
Hodgkin's LymphomaIndication
Malignant Solid NeoplasmIndication
Refractory Non-Hodgkin LymphomaIndication
MyelofibrosisIndication
Stage III Pancreatic CancerIndication
Prostate CancerIndication
Pancreatic AdenocarcinomaIndication
Cutaneous MelanomaIndication
FollicularIndication
Papillary Thyroid CancerIndication
Follicular Thyroid CancerIndication
Hürthle cell tumorIndication
Thyroid CarcinomaIndication
Hürthle Cell Thyroid NeoplasiaIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
LymphomaIndication
Malignant NeoplasmIndication
TumorIndication
NeoplasiaIndication
Anaplastic Thyroid CancerIndication
BRAF Mutation-Related TumorsIndication
Malignant Solid TumorIndication
Metastatic Thyroid CancerIndication
Stage IIIA Cutaneous Melanoma AJCC v7Indication
NOSIndication
Malignant GliomaIndication
Grade 3 GliomaDrug
DabrafenibClinical trial
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-20
Clinical trial
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway MutationsStatus: , Estimated PCD: 2024-06-30
Clinical trial
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)Status: Completed, Estimated PCD: 2021-08-23
Clinical trial
COMBI-APlus: Open-label, Phase IIIb Study of Dabrafenib in COMBInation With Trametinib in the Adjuvant Treatment of Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes of an Adapted Pyrexia AE-management Algorithm (Plus)Status: Completed, Estimated PCD: 2020-10-05
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CDRB436B2005CM to Provide Access to Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic MelanomaStatus:
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2020-08-11
Clinical trial
Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United StatesStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)Status: Recruiting, Estimated PCD: 2027-05-26
Clinical trial
A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and TrametinibStatus: Completed, Estimated PCD: 2021-12-10
Clinical trial
An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical ResectionStatus: Completed, Estimated PCD: 2017-06-30
Clinical trial
A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid CancerStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2026-08-30
Clinical trial
Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
TraMel-WT: A Stratified Dual-stratum Open-label Two-stage Phase 2 Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2026-11-25
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Clinical trial
A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma PatientsStatus: Withdrawn, Estimated PCD: 2017-11-17
Clinical trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated AmeloblastomaStatus: Completed, Estimated PCD: 2018-11-05
Clinical trial
Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Altering Adjuvant Therapy Based on Pathologic Response to Neoadjuvant Dabrafenib and Trametinib (ALTER-PATH NeoDT)Status: Completed, Estimated PCD: 2023-10-09
Clinical trial
A Phase II, Open-label Study of Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-01-02
Clinical trial
Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Efficacy of Immunotherapy in Melanoma Patients With Brain Metastases Treated With SteroidsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-02
Clinical trial
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant CancerStatus: Active (not recruiting), Estimated PCD: 2018-05-16
Clinical trial
A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK InhibitionStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive MelanomaStatus: Active (not recruiting), Estimated PCD: 2017-05-04
Clinical trial
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non-Small Cell Lung Cancer)Status: Active (not recruiting), Estimated PCD: 2025-04-02
Clinical trial
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and TrametinibStatus: Recruiting, Estimated PCD: 2024-06-20
Clinical trial
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyStatus: Terminated, Estimated PCD: 2022-12-30
Clinical trial
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA)Status: Active (not recruiting), Estimated PCD: 2024-12-08
Clinical trial
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2024-12-04
Clinical trial
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600EmStatus: Not yet recruiting, Estimated PCD: 2030-09-30
Document
DailyMed Label: TafinlarOrganization
Novartis Pharmaceuticals Corporation